Acadian Asset Management LLC Buys 174,451 Shares of Theravance Biopharma, Inc. $TBPH

Acadian Asset Management LLC increased its stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 121,993.7% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 174,594 shares of the biopharmaceutical company’s stock after acquiring an additional 174,451 shares during the quarter. Acadian Asset Management LLC owned about 0.35% of Theravance Biopharma worth $1,554,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Jane Street Group LLC boosted its position in shares of Theravance Biopharma by 169.2% during the first quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company’s stock worth $1,258,000 after acquiring an additional 88,540 shares during the last quarter. Park West Asset Management LLC boosted its position in shares of Theravance Biopharma by 0.6% during the first quarter. Park West Asset Management LLC now owns 1,804,244 shares of the biopharmaceutical company’s stock worth $16,112,000 after acquiring an additional 11,256 shares during the last quarter. AQR Capital Management LLC bought a new position in shares of Theravance Biopharma during the first quarter worth $101,000. PDT Partners LLC boosted its position in shares of Theravance Biopharma by 135.1% during the first quarter. PDT Partners LLC now owns 88,577 shares of the biopharmaceutical company’s stock worth $791,000 after acquiring an additional 50,901 shares during the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in shares of Theravance Biopharma during the first quarter worth $419,000. Institutional investors own 99.10% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on TBPH. B. Riley began coverage on shares of Theravance Biopharma in a research report on Friday, September 12th. They set a “buy” rating and a $28.00 target price for the company. Wall Street Zen upgraded shares of Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 16th. Jones Trading upgraded shares of Theravance Biopharma to a “strong-buy” rating and set a $24.00 price objective for the company in a research report on Tuesday, June 17th. Zacks Research upgraded shares of Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 15th. Finally, BTIG Research increased their price objective on shares of Theravance Biopharma from $24.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, June 27th. Three research analysts have rated the stock with a Strong Buy rating and two have assigned a Buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Strong Buy” and an average price target of $23.00.

Insider Activity

In related news, SVP Rhonda Farnum sold 10,000 shares of the firm’s stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $11.39, for a total value of $113,900.00. Following the transaction, the senior vice president owned 326,918 shares of the company’s stock, valued at $3,723,596.02. This trade represents a 2.97% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 6.90% of the company’s stock.

Theravance Biopharma Trading Down 3.7%

Theravance Biopharma stock opened at $13.87 on Wednesday. The firm has a 50-day moving average price of $12.51 and a 200-day moving average price of $10.67. The firm has a market capitalization of $698.49 million, a PE ratio of 57.79 and a beta of 0.05. Theravance Biopharma, Inc. has a 12-month low of $7.88 and a 12-month high of $14.55.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.